Journal Articles

Tanz LJ, Ertl A, Mansfield R, Casillas SM. Comparison of persons who died of drug overdoses with and without evidence of hepatitis C, United States, 2019–2024. Drug and Alcohol Dependence, 2026. https://doi.org/10.1016/j.drugalcdep.2026.113295

Quader ZS, Tanz LJ, Gladden RM, et al. U.S. Drug Overdose Deaths that Occurred in Isolation, 2022-2024. NEJM Evid. 2026 Jul 22:EVIDpha2600113. doi: 10.1056/EVIDpha2600113

Shih Y, Zhang K, Schmit K, et al. Patterns of postoperative opioid dispensing among Medicaid beneficiaries, 2016–2017 and 2021–2022. The Journal of Pain, 2026; 47. https://doi.org/10.1016/j.jpain.2026.106361

Aslam MV, Rooks-Peck C, Florence C, et al. Adverse Effects of Non-Medical Use of Cannabis or Opioids Associated with Adverse Childhood Experiences. International Journal of Environmental Research and Public Health. 2026; 23(5):574. https://doi.org/10.3390/ijerph23050574

Dernbach MR, Yeh M, Schier J, et al. Characterizing pediatric xylazine exposures reported to United States poison centers, 2010-2024. Clinical Toxicology, 1–9. https://doi.org/10.1080/15563650.2026.2636639

Nataraj N, Chen Y, Stewart A, et al. Burden of overdoses among persons with opioid use disorder in the United States, 2025–2028: A simulation modeling study. The Lancet Regional Health – Americas, Volume 56, 101435. https://doi.org/10.1016/j.lana.2026.101435

Bixler D, Bennett C. C, Yin S, Thomson A, Miller K, Peruski A, Gupta N, & Appalachian Jurisdiction Partners. Fatal Overdose, Acute Viral Hepatitis, and Human Immunodeficiency Virus Attributed to Injection Drug Use, Appalachian Region of the United States, 2000-2023. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaf730

Dowell D, Nataraj N, Rikard M, Park J, Zhang K, Baldwin G. Why have overdose deaths decreased? Widespread fentanyl saturation and decreased drug use among key drivers. The Lancet Regional Health – Americas, Volume 0, Issue 0, 101226. doi: 10.1016/j.lana.2025.101226

Liu S, Casillas S, Ussery E, Sheppard M, Vivolo-Kantor A. Trends of all opioid-, heroin-, and fentanyl-involved nonfatal overdoses in the United States, October 2020–April 2025. Drug and Alcohol Dependence. 2025;263:112886. doi:10.1016/j.drugalcdep.2025.112886

Rikard SM, Doshi K, Guy GP, Schmit KM. Awareness of and Beliefs About Naloxone Among Adults. JAMA Health Forum. 2025;6(6):e251867. doi:10.1001/jamahealthforum.2025.1867.

Guy GP Jr, Jones CM, Rikard SM, Zhang K, Olsen Y. Prescriber-Level Changes in Buprenorphine Dispensing in the USA Before and After Federal Policy Changes Aimed at Increasing Prescribing. J Gen Intern Med. 2025 Jun 25. doi: 10.1007/s11606-025-09655-8.

Tran EL, Rikard SM, Guy GP Jr, Mikosz CA. The Mainstreaming Addiction Treatment Act and Pharmacist-Prescribed Buprenorphine. JAMA. 2025 Jun 16. doi: 10.1001/jama.2025.7151.

Ragan-Burnett K, Schieber L, Terranella A, Mikosz C. Substance Use Screening, Brief Intervention, and Referral to Treatment Among Youth-Serving Clinicians. JAMA Netw Open. 2025;8(5):e2511579. doi:10.1001/jamanetworkopen.2025.11579.

Guy GP, Jones CM, Rikard M, et al. Individuals Dispensed Buprenorphine in the United States Before and After Federal Policy Changes Aimed at Increasing Access. Journal of Addiction Medicine. February 19, 2025. DOI: 10.1097/ADM.0000000000001457.

Han B, Jones CM, Volkow ND, et al. Prescription Stimulant Use, Misuse, and Use Disorder Among US Adults Aged 18 to 64 Years. JAMA Psychiatry. doi:10.1001/jamapsychiatry.2025.0054.

Terranella A, Jiang X, Bly C, et al. Gabapentinoid Dispensing to Children and Adolescents in the United States. AJPM. Published online February 3, 2025. doi:10.1016/j.amepre.2025.01.026.

Wisdom A, Haddad S, Govindu M, Higgins F, Filion N, Sullivan K, Rooks-Peck C. Overdose prevention activities led by local public health departments, 2019-2023. Subst Abuse Treat Prev Policy. 2024 Jun 4;19(1):29. doi: 10.1186/s13011-024-00612-y.

Wang P, Williams RJ, Chen W, et al. Chemical Composition of Electronic Vaping Products From School Grounds in California. Nicotine Tob Res. 2024 Jul 22;26(8):991-998. doi: 10.1093/ntr/ntae042.

Villamil VI, Underwood N, Cremer LJ, Rooks-Peck CR, Jiang X, Guy GP. Barriers to retention in medications for opioid use disorder treatment in real-world practice. J Subst Use Addict Treat. 2024 May;160:209310. doi: 10.1016/j.josat.2024.209310.

Swedo E, Anderson K, Okwori G, et al. Adolescents' Adverse Childhood Experiences, Poor Mental Health, and Substance Use During the COVID-19 Pandemic. J Adolesc Health. 2025 Jan;76(1):52-61. doi: 10.1016/j.jadohealth.2024.07.030.

Schieber LZ, Rikard SM, Strahan AE, Losby JL, Guy GP Jr. Urban-Rural Differences in Opioid Dispensing, U.S., 2019-2021. Am J Prev Med. 2024 Jun;66(6):1071-1074. doi: 10.1016/j.amepre.2024.01.013.

Myrick A, Adams, CA, Cremer LJ, et al. Local Supports to Break the Cycle: A Description of Intersectional Interventions to Address Adverse Childhood Experiences and Drug Overdose. J Public Health Manag Pract. 2025 Mar-Apr 01;31(2):227-233. doi: 10.1097/PHH.0000000000002042.

McCabe LH, Masuda N, Casillas S, Danneman N, Alic A, Law R. Network analysis of U.S. non-fatal opioid-involved overdose journeys, 2018-2023. Appl Netw Sci. 2024;9(1):68. doi: 10.1007/s41109-024-00661-z.

Magnusson K, Glidden E, Mustaquim D, et al; Toxicology Investigators Consortium (ToxIC) Study Group. Differences in Drug Poisonings Among Those Who Identify as Transgender Compared to Cisgender: An Analysis of the Toxicology Investigators Consortium (ToxIC) Core Registry, United States 2017-2021. Clin Ther. 2024 Dec;46(12):953-959. doi: 10.1016/j.clinthera.2024.08.018.

Kobernik EK, Ford ND, Levecke M, Galang RR, Hoots B, Roehler DR, Ko JY. Marijuana Use among Pregnant and Nonpregnant Women of Reproductive Age, 2013-2019. Subst Use Misuse. 2024;59(5):690-698. doi: 10.1080/10826084.2023.2294974.

Kilmer G, Jones SE, Rico A, Houston A, Lim C, Leon-Nguyen M, Asher AK. Changes in Illicit Drug Use Among High School Students in Southeastern U.S. States-2009 to 2019. J Prev (2022). 2024 Oct;45(5):815-831. doi: 10.1007/s10935-024-00791-1.

Jiang X, Strahan AE, Zhang K, Guy GP Jr. Trends in Out-of-Pocket Costs for and Characteristics of Pharmacy-Dispensed Naloxone by Payer Type. JAMA. 2024 Feb 27;331(8):700-702. doi: 10.1001/jama.2023.26969.

Jiang X, Govoni TD, Illg Z, Connolly S, Green JL, Guy GP Jr. Sources of nonmedically used prescription psychotherapeutic drugs using real-world data from adolescents and adults assessed for substance use treatment--2014-2022. Res Social Adm Pharm. 2024 Feb;20(2):209-214. doi: 10.1016/j.sapharm.2023.10.014.

Hersey C, Shoemaker-Hunt S, Parchman M, Childs E, Le J, Sargent W. Implementation and adaptation of clinical quality improvement opioid measures. Healthc (Amst). 2024 Dec;12(4):100753. doi: 10.1016/j.hjdsi.2024.100753.

Guy GP Jr, Adams EK, Redd SK, Dunlop AL. Effects of Georgia's Medicaid Family Planning Waiver on Pregnancy Characteristics and Birth Outcomes. Womens Health Issues. 2024 Mar-Apr;34(2):125-134. doi: 10.1016/j.whi.2023.11.004.

Boehnke KF, Sinclair R, Gordon F, Roehler DR, Smith T, Hoots B. Data Quality in State Registry Reports of Medical Cannabis Patients in the United States. Am J Public Health. 2024 Nov;114(S8):S685-S693. doi: 10.2105/AJPH.2024.307728.

Board A, Vivolo-Kantor AM, Kim S, Tran EL, Thomas SA, Terplan M, Smid MC, Sanjuan PM, Wright T, Davidson A, Wachman EM, Rood KM, Morse D, Chu E, Miele K. Using ICD Codes Alone May Misclassify Overdoses Among Perinatal People. AJPM. 2024:S0749-3797(24)00418-5. doi: 10.1016/j.amepre.2024.12.001

Board A, D'Angelo DV, Miele K, Asher A, Salvesen von Essen B, Denny CH, Terplan M, Dunkley J, Kim SY. Naloxone Use During Pregnancy-Data From 26 US Jurisdictions, 2019-2020. J Addict Med. 2024 Nov-Dec 01;18(6):711-714. doi: 10.1097/ADM.0000000000001337.

Baldwin GT, Vivolo-Kantor A, Hoots B, Roehler DR, Ko JY. Current Cannabis Use in the United States: Implications for Public Health Research. American journal of public health. 2024;114(S8):S624–S627. https://doi.org/10.2105/AJPH.2024.307823

Austin AE, DePadilla L, Niolon P, Stone D, Bacon S. Intersection of adverse childhood experiences, suicide and overdose prevention. Inj Prev. 2024 Oct 1;30(5):355-362. doi: 10.1136/ip-2024-045295.

Austin AE, Anderson KN, Goodson M, Holditch Niolon P, Swedo EA, Terranella A, Bacon S. Screening for Adverse Childhood Experiences: A Critical Appraisal. Pediatrics. 2024;154(6): e2024067307. https://doi.org/10.1542/peds.2024-067307.

Tran EL, Dorsey AN, Miele K, et al. Patterns of Medication for Opioid Use Disorder During Pregnancy, 7 Clinical Sites, MATernaL and Infant clinical NetworK (MAT-LINK), 2014–2021. Journal of Addiction Medicine. 2024 Dec 12. doi: 10.1097/ADM.0000000000001426

Rikard SM, Schmit KM, Guy GP. Patient-Provider Interactions and Access to Prescription Medications Among Adults with Chronic Pain in the United States, 2023. J GEN INTERN MED (2024). https://doi.org/10.1007/s11606-024-09271-y

Lee E, Rikard SM, Guy G, Terranella A, et al. Trends in Buprenorphine Dispensing Among Adolescents and Young Adults in the US. JAMA. Published online December 23, 2024. doi:10.1001/jama.2024.24121

Quader ZS, Park J, Krishnan SD, et al. Non-fatal drug overdose surveillance using hospital discharge data: a comparison between the Drug Overdose Surveillance and Epidemiology (DOSE) system and the Healthcare Cost and Utilisation Project, 18 states, 2018–2020. Injury Prevention Published Online First: 24 December 2024. doi: 10.1136/ip-2024-045446

Hoots BE, Roehler DR. Closing Gaps Between Cannabis Policy and Scientific Understanding. Am J Public Health. 2024 Nov;114 (S621-S622). https://doi.org/10.2105/AJPH.2024.307883

Varma P, DePadilla L, Czeisler MÉ, et al. (2024). Substance use and help seeking as coping behaviors among parents and unpaid caregivers of adults in the United States during the COVID-19 pandemic. The American Journal of Drug and Alcohol Abuse, 1–13. https://doi.org/10.1080/00952990.2024.2394970

Nguyen A, Wang J, Holland KM, Ehlman DC, Welder LE, Miller KD, Stone DM. Trends in Drug Overdose Deaths by Intent and Drug Categories, United States, 1999‒2022. Am J Public Health. 2024 Oct;114(10):1081-1085. doi: 10.2105/AJPH.2024.307745.

Liu SJ, Smith H, Krishnasamy V, Gladden RM. Development of a Definition to Identify Severe Opioid Overdoses Treated in Emergency Departments, 2019-2022. J Public Health Manag Pract. 2024 Sep 24. doi: 10.1097/PHH.0000000000002045.

Ragan K, Curtis CR, Schmit K, et al. Physicians’ Self-reported Knowledge and Behaviors Related to Prescribing Opioids for Chronic Pain and Diagnosing Opioid Use Disorder - DocStyles, 2020. AJPM Focus. September 2024; 3(6). https://doi.org/10.1016/j.focus.2024.100269

Terranella A, Guy G Jr, Mikosz C. Naloxone Dispensing to Youth Ages 10–19: 2017–2022. Pediatrics. 2024;154(4). https://doi.org/10.1542/peds.2023-065137

Ussery EN, Rennick M, Vivolo-Kantor AM, et al. Developing a Cascade of Care Framework and Surveillance Indicators to Monitor Linkage to and Retention in Care for Substance Use Disorder. Public Health Reports®. 2024. doi:10.1177/00333549241266994

Casillas SM, Stokes EK, Vivolo-Kantor AM. Comparison of emergency medical services and emergency department encounter trends for nonfatal opioid-involved overdoses, nine states, United States, 2020-2022. Ann Epidemiol. 2024 Jun 26; 97:38-43. doi: 10.1016/j.annepidem.2024.06.007.

Corry B, Cremer LJ, Donnelly C, Sargent WM, et al. Changes in opioid prescribing and prescription drug monitoring program utilization following electronic health record integration—Massachusetts, 2018. Pain Medicine. June 2024; 25(6):380–386. https://doi.org/10.1093/pm/pnae012

Jiang X, Guy GP, Dever JA, et al. Association Between Length of Buprenorphine or Methadone Use and Nonprescribed Opioid Use Among Individuals with Opioid Use Disorder: A Cohort Study. Substance Use & Addiction Journal. 2024;0(0). doi:10.1177/29767342241266038

Connolly S, Terranella A, Guy GP, Mikosz CA. Pattern of Buprenorphine Treatment Retention Among Youth Aged 10 to 18 Years—US, 2015 to 2021. JAMA Pediatr. Published online July 29, 2024. doi:10.1001/jamapediatrics.2024.2502

Han B, Jones CM, Einstein EB, Dowell D, Compton WM. Prescription Opioid Use Disorder Among Adults Reporting Prescription Opioid Use With or Without Misuse in the United States. J Clin Psychiatry. 2024 Jul 15;85(3):24m15258. doi: 10.4088/JCP.24m15258.

Jiang X, Guy GP, Schmit K, Hoots B, Roehler DR, et al. Substance Use Patterns and Characteristics Using Real World Data from Adolescents Assessed for Substance Use and Treatment Planning-United States, 2017–2021. Substance Use & Misuse, 1–18. 2024. https://doi.org/10.1080/10826084.2024.2383609

Rikard SM, Strahan AE, Schieber LZ, Guy GP. Trends in Naloxone Dispensing From Retail Pharmacies in the US. JAMA. 2024 June 13. doi:10.1001/jama.2024.8323

Jones CM, Shoff C, Blanco C, et al. Overdose, Behavioral Health Services, and Medications for Opioid Use Disorder After a Nonfatal Overdose. JAMA Intern Med. 2024 June 17. doi:10.1001/jamainternmed.2024.1733

Jones CM, Zhang K, Han B, et al. Estimated Number of Children Who Lost a Parent to Drug Overdose in the US From 2011 to 2021. JAMA Psychiatry. 2024 May 8. doi:10.1001/jamapsychiatry.2024.0810

Barham CL, Strahan AE, Zhang K, et al. National- and State-Level Pharmacy-Based Buprenorphine Dispensing, United States 2019–2021. J GEN INTERN MED (2024). https://doi.org/10.1007/s11606-024-08829-0

Winston TR, Reed M, Roberts M, et al. Implementing a Needs Assessment to Advance Health Equity in Overdose Prevention and Surveillance Initiatives. Public Health Reports. 2024;0(0). doi:10.1177/00333549241239905

Nataraj N, Rikard SM, Zhang K, et al. Public Health Interventions and Overdose-Related Outcomes Among Persons With Opioid Use Disorder. JAMA Netw Open. 2024;7(4):e244617. doi:10.1001/jamanetworkopen.2024.4617

Boehnke KF, Sinclair R, Gordon F, Hosanagar A, Roehler DR, Smith T, Hoots B. Trends in U.S. Medical Cannabis Registrations, Authorizing Clinicians, and Reasons for Use From 2020 to 2022. Ann Intern Med. 2024 Apr 9. doi: 10.7326/M23-2811.

Corry B, Cremer LJ, Donnelly C, Sargent WM, Mells J, Kelly R, Reynolds J, Young LD. Changes in opioid prescribing and prescription drug monitoring program utilization following electronic health record integration - Massachusetts. Pain Medicine. 2024. https://doi.org/10.1093/pm/pnae012

Rikard MS, Nataraj N, Zhang K, Strahan A, Mikosz CA, Guy GP. Reply to Chang et al.. PAIN 165(4):p 959, April 2024. | DOI: 10.1097/j.pain.000000000000317

ElSherief M, Sumner S, Krishnasamy V, Jones C, Law R, Kacha-Ochana A, Schieber L, De Choudhury M. Identification of Myths and Misinformation About Treatment for Opioid Use Disorder on Social Media: Infodemiology Study. JMIR Form Res 2024;8:e44726. DOI: 10.2196/44726

Casillas SM, Pickens CM, Tanz LJ, et al. Estimating the ratio of fatal to non-fatal overdoses involving all drugs, all opioids, synthetic opioids, heroin or stimulants, USA, 2010–2020. Injury Prevention Published Online First: 30 January 2024. doi: 10.1136/ip-2023-045091

Strahan AE, Desai S, Zhang K, Guy GP. Trends in Out-of-Pocket Costs for and Characteristics of Pharmacy-Dispensed Buprenorphine Medications for Opioid Use Disorder Treatment by Type of Payer, 2015 to 2020. JAMA Netw Open. 2023;6(2):e2254590. doi:10.1001/jamanetworkopen.2022.54590

Dever JA, Hertz MF, Dunlap LJ, et al. The Medications for Opioid Use Disorder Study: Methods and Initial Outcomes From an 18-Month Study of Patients in Treatment for Opioid Use Disorder. Public Health Reports. 2024;0(0). doi:10.1177/00333549231222479

Terranella A, Guy G, Strahan A, Mikosz C. Out-of-Pocket Costs and Payer Types for Buprenorphine Among US Youth Aged 12 to 19 Years. JAMA Pediatrics. 2023;177(10):1096–1098. doi:10.1001/jamapediatrics.2023.2376

Joshi S, Rivera BD, Cerdá M, et al. One-Year Association of Drug Possession Law Change With Fatal Drug Overdose in Oregon and Washington. JAMA Psychiatry. 2023;80(12):1277–1283. doi:10.1001/jamapsychiatry.2023.3416

Jiang X, Govoni TD, Illg Z, Connolly S, et al. Sources of nonmedically used prescription psychotherapeutic drugs using real-world data from adolescents and adults assessed for substance use treatment–2014-2022. Research in Social and Administrative Pharmacy. 2023. https://doi.org/10.1016/j.sapharm.2023.10.014

Larochelle MR, Jones CM, Zhang K. Change in opioid and buprenorphine prescribers and prescriptions by specialty, 2016-2021. Drug Alcohol Depend. 2023;248:109933. doi:10.1016/j.drugalcdep.2023.109933

Rikard SM, Nataraj N, Zhang K, Strahan AE, Mikosz CA, Guy GP Jr. Longitudinal dose patterns among patients newly initiated on long-term opioid therapy in the United States, 2018 to 2019: an observational cohort study and time-series cluster analysis [published online ahead of print, 2023 Jul 27]. Pain. 2023;10.1097/j.pain.0000000000002994. doi:10.1097/j.pain.0000000000002994

Schieber LZ, Lopes-Cardozo B, Guy GP Jr. Substance Use Disorder and Health Outcomes in COVID-19 -the Need for a Better Research Method to Determine Total Substance Use Exposure-Reply [published online ahead of print, 2023 Jul 5]. JAMA Psychiatry. 2023;10.1001/jamapsychiatry.2023.2116. doi:10.1001/jamapsychiatry.2023.2116

Sargent WM Jr, Mikosz CA, Baker EL. Supporting Evidence-Based Care Through Informatics Innovation to Address the Overdose Epidemic. J Public Health Manag Pract. 2023;29(4):598-600. doi:10.1097/PHH.0000000000001754

Giabbanelli, PJ, Rice, KL, Nataraj, N. et al. A systems science approach to identifying data gaps in national data sources on adolescent suicidal ideation and suicide attempt in the United States. BMC Public Health 23, 627 (2023). https://doi.org/10.1186/s12889-023-15320-8

Pickens, CM, Jones, CM, Guy, GP. et al. Associations between prescription stimulant use as prescribed, nonmedical use, and illicit stimulant use among adults evaluated for substance use treatment, 2017-2021. Drug and Alcohol Dependence Reports, 7 (2023). https://doi.org/10.1016/j.dadr.2023.100153

Schier J, Chang A, Kapil V. Medication-Associated Diethylene Glycol Mass Poisoning – A Preventable Cause of Illness and Death [published online ahead of print, 2023 Mar 2]. N Engl J Med. 2023. doi:10.1056/NEJMp2215840

Scholl L, Liu S, Pickens C. Suspected Nonfatal Cocaine-Involved Overdoses Overall and With Co-involvement of Opioids. Journal of Public Health Management and Practice. 2023 March 03. DOI: 10.1097/PHH.0000000000001719

Tanz LJ, Jones CM, Davis NL, et al. Trends and Characteristics of Buprenorphine-Involved Overdose Deaths Prior to and During the COVID-19 Pandemic. JAMA Netw Open. 2023;6(1):e2251856. doi:10.1001/jamanetworkopen.2022.51856

Terranella, A, Guy, GP, Mikosz, C. Buprenorphine Dispensing Among Youth Aged ≤19 Years in the United States: 2015-2020. Pediatrics. 2023. e2022058755. https://doi.org/10.1542/peds.2022-058755

Glidden E, Suen K, Mustaquim D, et al. Characterization of Nonfatal Opioid, Cocaine, Methamphetamine, and Polydrug Exposure and Clinical Presentations Reported to the Toxicology Investigators Consortium Core Registry, January 2010-December 2021 [published online ahead of print, 2023 Jan 17]. J Med Toxicol. 2023. https://doi.org/10.1007/s13181-022-00924-0

Strahan AE, Desai S, Zhang K, et al. Trends in Out-of-Pocket Costs for and Characteristics of Pharmacy-Dispensed Buprenorphine Medications for Opioid Use Disorder Treatment by Type of Payer, 2015 to 2020. JAMA Netw Open. 2023;6(2):e2254590. doi:10.1001/jamanetworkopen.2022.54590

Childs, E, Tano, CA, Mikosz, CA, et. al. Factors That Affect Opioid Quality Improvement Initiatives in Primary Care: Insights from Ten Health Systems. The Joint Commission Journal on Quality and Patient Safety. October 2022. https://doi.org/10.1016/j.jcjq.2022.10.002

Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. Prescribing Opioids for Pain — The New CDC Clinical Practice Guideline. N Engl J Med. 2022 Nov 3; Online ahead of print. DOI: 10.1056/NEJMp2211040

Mital, S, O’Brien, M. From Silos to Synergy: Public Health and Public Safety Collaborations to Reduce Drug Overdose. Journal of Public Health Management and Practice. 28(Supplement 6):S271-S272, November/December 2022. doi: 10.1097/PHH.0000000000001627

Mital, S, Wisdom, AC, Wolff, JG. Improving Partnerships Between Public Health and Public Safety to Reduce Overdose Deaths: An Inventory From the CDC Overdose Data to Action Funding Initiative. Journal of Public Health Management and Practice. 28(Supplement 6):S279-S285, November/December 2022. doi: 10.1097/PHH.0000000000001637

Rubel, S, Neubert, P, Navarretta, N, et. al. Facilitating Overdose Risk Mitigation Among Patients Following a Clinician Office Closure: A Connecticut Case Study of the Opioid Rapid Response Program. Journal of Public Health Management and Practice. 28(Supplement 6):S381-S387, November/December 2022. doi: 10.1097/PHH.0000000000001555

Roe, SS, Cordelli, R, Shutz, B, Rubel, S. Pilot Case Study: A Framework for Multisector Public Health and Safety Teams Addressing the Overdose Epidemic. Journal of Public Health Management and Practice. 28(Supplement 6):S372-S380, November/December 2022. doi: 10.1097/PHH.0000000000001559

Wolff, J, Gitukui, S, O’Brien,M, Mital, S., Noonan, RK. The Overdose Response Strategy: Reducing Drug Overdose Deaths Through Strategic Partnership Between Public Health and Public Safety. Journal of Public Health Management and Practice. 28(Supplement 6):S359-S366, November/December 2022. doi: 10.1097/PHH.0000000000001580

Wisdom, AC, Villamil, V, Govindu, M, et. al. The Martinsburg Initiative: A Collaboration Between Public Safety, Public Health, and Schools to Address Trauma and Substance Use. Journal of Public Health Management and Practice. 28(Supplement 6):S355-S358, November/December 2022. doi: 10.1097/PHH.0000000000001591

Worthington, N, Gilliam, T, Mital, S. First Responder Assertive Linkage Programs: A Scoping Review of Interventions to Improve Linkage to Care for People Who Use Drugs. Journal of Public Health Management and Practice. 28(Supplement 6):S302-S310, November/December 2022. doi: 10.1097/PHH.0000000000001611

Houry, D. Collaborative Partnerships Are Key to Address the Overdose Crisis: Public Health and Public Safety. Journal of Public Health Management and Practice. 28(Supplement 6):S273-S274, November/December 2022. doi: 10.1097/PHH.0000000000001639

Seth P, Baldwin GT, Davis NL, Jones CM. Clarifying CDC’s Efforts to Quantify Overdose Deaths. Public Health Reports. 2022;0(0). doi:10.1177/00333549221123586

Kariisa M, Seth P, Jones CM. Increases in Disparities in US Drug Overdose Deaths by Race and Ethnicity: Opportunities for Clinicians and Health Systems. JAMA. Published online July 19, 2022. doi:10.1001/jama.2022.12240

Dunph CC, Zhang K, Likang X, Guy GP. Racial‒Ethnic Disparities of Buprenorphine and Vivitrol Receipt in Medicaid, American Journal of Preventive Medicine. https://doi.org/10.1016/j.amepre.2022.05.006. Epub 2022 July 6.

Zhang K, Strahan AE, Guy GP, Larochelle MR. Trends in Concurrent Opioid and Benzodiazepine Prescriptions in the United States, 2016 to 2019. Annals of Internal Medicine. [Epub 7 June 2022]. doi:10.7326/M21-4656

Wisdom AC, Govindu M, Liu SJ, Meyers CM, Mellerson JL, Gervin DW, DePadilla L, Holland KM. Adverse Childhood Experiences and Overdose: Lessons From Overdose Data to Action. Am J Prev Med. 2022 Jun;62(6S1):S40-S46. doi: 10.1016/j.amepre.2021.11.015.

Corry B, Underwood N, Cremer LJ, Rooks-Peck CR, Jones C. County-level sociodemographic differences in availability of two medications for opioid use disorder: United States, 2019. Drug Alcohol Depend. 2022 May 13;236:109495. doi: 10.1016/j.drugalcdep.2022.109495. Epub ahead of print.

Zhang K, Jones CM, Compton WM, Guy GP, Evans ME, Volkow ND. Association Between Receipt of Antidepressants and Retention in Buprenorphine Treatment for Opioid Use Disorder: A Population-Based Retrospective Cohort Study. J Clin Psychiatry. 2022;83(3):21m14001. Published 2022 Apr 27. doi:10.4088/JCP.21m14001

Quinn K, Kumar S, Hunter CT, O’Donnell J, Davis NL. Naloxone administration among opioid-involved overdose deaths in 38 United States jurisdictions in the State Unintentional Drug Overdose Reporting System, 2019. Drug and Alcohol Dependence. 235 (June 2022): 109467. https://doi.org/10.1016/j.drugalcdep.2022.109467.

Seitz AE, Janiszewki KA, Guy GP, Tapscott RT, Einstein EB, Meyer TE, Tierney J, Staffa J, Jones CM, Compton WM. Evaluating opioid analgesic prescribing limits: A narrative review. Pharmacoepidemiology & Drug Safety. https://doi.org/10.1002/pds.5425. Epub 2022 Mar 5.

Nataraj N, Strahan AE, Guy GP, Losby JL, Dowell D. Dose Tapering, Increases, and Discontinuity among Patients on Long-Term High-Dose Opioid Therapy in the United States, 2017-2019. Drug and Alcohol Dependence. https://doi.org/10.1016/j.drugalcdep.2022.109392. Epub 2022 Mar 3.

Underwood N, Cance JD, Kane H, Hennessy C, Christensen A, Rooks-Peck C. Understanding State-Level Variations in Implementing Academic Detailing for Prescribing Opioids (Findings from 11 States within the US). Pain Medicine. https://doi.org/10.1093/pm/pnac039. Epub 2022 Feb 26.

Roehler DR, Hoots BE, Holland KM, Baldwin G, Vivolo-Kantor A. Trends and characteristics of cannabis-associated emergency department visits in the United States, 2006-2018. Drug and Alcohol Dependence. doi.org/10.1016/j.drugalcdep.2022.109288. Epub 2022 Jan 10.

O’Donnell J, Gladden RM, Kariisa M, Mattson C. Using death scene and toxicology evidence to define involvement of heroin, pharmaceutical morphine, illicitly manufactured fentanyl, and pharmaceutical fentanyl in opioid overdose deaths, 38 states and the District of Columbia, January 2018–December 2019. Addiction. doi: 10.1111/add.15768. Epub 2021 Dec 9.

Jiang X, Guy GP, Dunphy C, Pickens CM, Jones CM. Characteristics of adults reporting illicitly manufactured fentanyl or heroin use or prescription opioid misuse in the United States, 2019. Drug and Alcohol Dependence. doi: doi.org/10.1016/j.drugalcdep.2021.109160. Epub 2021 Oct 31.

Cremer LJ, Underwood N, Robinson A, Guy GP Rooks-Peck CR. Association between county-level sociodemographic characteristics and county-level differences in opioid dispensing. Preventive Medicine Reports. (2021); 24, 101612. doi: 10.1016/j.pmedr.2021.101612.

Hoots BE. Opioid Overdose Surveillance: Improving Data to Inform Action. Public Health Reports. 2021 Nov-Dec;136(1_suppl):5S-8S. doi: 10.1177/00333549211020275.

Pickens CM, Scholl L, Liu S, Smith H, Snodgrass S. Development and Validation of a Syndrome Definition for Suspected Nonfatal Unintentional/Undetermined Intent Stimulant-Involved Overdoses. Public Health Reports. November 2021. doi: 10.1177/00333549211054489.

Pickens CM, Hoots BE, Casillas SM, Scholl L. Prevalences of and characteristics associated with single- and polydrug-involved U.S. Emergency Department Visits in 2018. Addictive Behaviors. Oct 20 2021;125:107158. doi:10.1016/j.addbeh.2021.107158

Dunphy C, Zhang K, Guy GP, Jones CM. Naloxone dispensing among the commercially insured population in the United States from 2015 to 2018. Preventive Medicine. 2021, Sep 29. doi: 10.1016/j.ypmed.2021.106820

Jones CM, Houry D, Han B, Baldwin G, Vivolo‐Kantor A, Compton WM. Methamphetamine use in the United States: epidemiological update and implications for prevention, treatment, and harm reduction. Annals of the New York Academy of Sciences. 2021, 24 September. https://doi.org/10.1111/nyas.14688

Scholl L, Liu S, Vivolo-Kantor A, Board A, Stein Z, Roehler D, McGlone L, Hoots, BE, Mustaquim D, Smith H. Development and Validation of a Syndrome Definition to Identify Suspected Nonfatal Heroin-Involved Overdoses Treated in Emergency Departments. Journal of Public Health Management and Practice. 27(4): 369-378. July/August 2021. doi: 10.1097/PHH.0000000000001271

Mustaquim D, Jones CM, Compton WM. Trends and correlates of cocaine use among adults in the United States, 2006-2019. Addiction. doi: 10.1016/j.addbeh.2021.106950. Epub 2021 Apr 20.

Dunphy C, Peterson C, Zhang K, Jones CM. Do out-of-pocket costs influence retention and adherence to medications for opioid use disorder? Drug Alcohol Dependence. doi: 10.1016/j.drugalcdep.2021.108784. Epub 2021 May 21.

Guy GP, Khushalani JS, Jackson H, Sims RS, Arifkhanova A. Trends in State-Level Pharmacy-Based Naloxone Dispensing Rates, 2012–2019. American Journal of Preventive Medicine. 2021, Oct 18. doi: 10.1016/j.amepre.2021.05.042

Kariisa M, Seth P, Scholl L, Wilson N, Davis N. Drug Overdose Deaths Involving Cocaine and Psychostimulants with Abuse Potential among Racial and Ethnic Groups – United States, 2004-2019. Drug and Alcohol Dependence. 2021, Aug 28; 227: 109001. doi: 10.1016/j.drugalcdep.2021.109001

Underwood N, Cremer L, Cance JD, Williams J, Guy GP, Zule W. The impact of community-level prevention strategies on high-dose opioid dispensing rates: 2014–2019. Drug and Alcohol Dependence. 2021, Oct 1. 227: 108988. doi: 10.1016/j.drugalcdep.2021.108988

Schauer, G.L., Dilley J.A., Roehler D.R., et al. Cannabis Sales Increases during COVID-19: Findings from Alaska, Colorado, Oregon, and Washington. International Journal of Drug Policy. 2021. Vol 98. 103384. ISSN 0955-3959. doi: 10.1016/j.drugpo.2021.103384.

Robinson AB, Ali N, Costa O, Rooks-Peck C, Sorensen-Alawad A, Ballard J, Lowerre K, Fondario A. A Thematic Analysis of Overdose Prevention and Response Efforts in States Experiencing Declines in Rates of Opioid-Involved Overdose Deaths. Public Health Rep. 2021. doi: 10.1177/00333549211026816.

Compton, WM, Jones CM. Substance Use among Men Who Have Sex with Men. NEJM. (385)4: 352-356. 2021. doi: 10.1056/NEJMra2033007.

Vivolo-Kantor AM, Smith H, Scholl L. Differences and similarities between emergency department syndromic surveillance and hospital discharge data for nonfatal drug overdose. Annals of Epidemiology. 2021.ISSN 1047-2797. doi: 10.1016/j.annepidem.2021.05.008.

Goldstick JE, Guy GP, Losby JL, Baldwin G, Myers M, Bohnert ASB. Changes in Initial Opioid Prescribing Practices After the 2016 Release of the CDC Guideline for Prescribing Opioids for Chronic Pain. JAMA. 2021;4(7):e2116860. doi:10.1001/jamanetworkopen.2021.16860

Underwood N, Rooks-Peck C, Ali N, Wisdom A, Costa O, Robinson A, Mells J and Bacon S. State-led opioid overdose prevention efforts: Challenges, solutions and lessons learned from the CDC Prevention for States Program (PfS). Substance Abuse. 2021. doi: 10.1080/08897077.2021.1903649

Cruz K, Deokar A, Feldman SJ, Patrick H. Special Report from the CDC: Readiness to surge: State health departments’ workforce infrastructure during the opioid crisis. J Safety Res. 2021; 77: 324-327. doi: 10.1016/j.jsr.2021.03.012.

Vivolo-Kantor, A, Pasalic E, Liu S, Martinez PD, Gladden RM. Defining indicators for drug overdose emergency department visits and hospitalisations in ICD-10-CM coded discharge data. Injury Prevention. 2021; 27 (S1): i56-i61. http://dx.doi.org/10.1136/injuryprev-2019-043521

Baldwin GT, Seth P, Noonan RK. Continued Increases in Overdose Deaths Related to Synthetic Opioids: Implications for Clinical Practice. JAMA. Published online February 11, 2021. doi:10.1001/jama.2021.1169

Holland KM, Jones C, Vivolo-Kantor AM, et. al. Trends in US Emergency Department Visits for Mental Health, Overdose, and Violence-Related Outcomes Before and During the COVID-19 Pandemic. JAMA Psychiatry. 2021, Feb 3. doi:10.1001/jamapsychiatry.2020.4402

Jones CM, Guy GP, Board A. Comparing actual and forecasted numbers of unique patients dispensed select medications for opioid use disorder, opioid overdose reversal, and mental health, during the COVID-19 pandemic, United States, January 2019 to May 2020. Drug and Alcohol Dependence. 2021, Feb 1. 219(2021). doi: 10.1016/j.drugalcdep.2020.108486

Roehler DR, Olsen EO, Mustaquim D, Vivolo-Kantor AM. Roehler D, Olsen E, Mustaquim D, Vivolo-Kantor D. Suspected nonfatal opioid and other drug-related overdoses among youth in the US, 2016-2019. Pediatrics. 2020, Dec 14. 2021;147(1). doi: 10.1542, 2020.003491

Florence C, Luo F, Rice K. The economic burden of opioid use disorder and fatal opioid overdose in the United States, 2017. Drug and Alcohol Dependence. 2020, Oct 27. doi: 10.1016/j.drugalcdep.2020.108350

Board AR, Guy GP, Jones CM, Hoots B. Trends in Stimulant Dispensing by Age, Sex, State of Residence, and Prescriber Specialty — United States, 2014–2019. Drug and Alcohol Dependence. 2020, Sep 15. doi: 10.1016/j.drugalcdep.2020.108297

Strahan AE, McKenna C, Miller GF, Guy GP. Prevalence of Nonpharmacologic and Pharmacologic Therapies Among Noncancer Chronic Pain–Associated Ambulatory Care Visits, 2016. American Journal of Preventive Medicine. 2020, Aug 22. doi: 10.1016/j.amepre.2020.04.02

Mital S, Wolff J, Carroll JJ, The relationship between incarceration history and overdose in North America: A scoping review of the evidence. Drug and Alcohol Dependence. 2020, May 24. 213:108088. doi: 10.1016/j.drugalcdep.2020.108088

Roehler DR, Guy GP Jr, Jones CM. Buprenorphine prescription dispensing rates and characteristics following federal changes in prescribing policy, 2017-2018: A cross-sectional study. Drug and Alcohol Dependence. 2020, May 25. 213:108083. doi: 10.1016/j.drugalcdep.2020.108083

Mikosz CA, Zhang K, Haegerich T, Xu L, Losby JL, Greenspan A, Baldwin G, Dowell D. Indication-Specific Opioid Prescribing for US Patients with Medicaid or Private Insurance, 2017. JAMA Network Open. 2020, May 11. 3(5):e204514. doi: 10.1001/jamanetworkopen.2020.4514

Jones CM, Olsen EO, ODonnell J, Mustaquim D. Resurgent Methamphetamine Use At Treatment Admission in the United States, 2008-2017. American Journal of Public Health. 2020, March 11. 110, 509-516. doi: 10.2105/AJPH.2019.305527

Hoots B, Vivolo-Kantor A, Seth P. The rise in nonfatal and fatal overdoses involving stimulants with and without opioids in the United States. Addiction. Epub 2020, Jan 7. doi: 10.1111/add.14878

Haegerich T, Jones C, Cote PO, Robinson A, Ross L. Evidence for State, Community and Systems-Level Prevention Strategies to Address the Opioid Crisis. Drug and Alcohol Dependence. 2019; doi:10.1016/j.drugalcdep.2019.107563

Guy G, Zhang K, Halpin J, Sargent W. An Examination of Concurrent Opioid and Benzodiazepine Prescribing in Nine States, 2015. American Journal of Preventive Medicine. doi:10.1016/j.amepre.2019.06.007

Houry, D, Adams, J. Emergency Physicians and Opioid Overdoses: A Call to Aid. Annals of Emergency Medicine, doi: 10.1016/j.annemergmed.2019.07.020

Jones C, Compton W, Vythilingam M. Naloxone Co-prescribing to Patients Receiving Prescription Opioids in the Medicare Part D Program, United States, 2016-2017. JAMA Network. 2019;322(5):462-464. doi: 10.1001/jama.2019.7988

Bohm M, Bridwell L, Zibbell J, Zhang K. Heroin and Healthcare: Patient Characteristics and Healthcare Prior to Overdose. The American Journal of Managed Care. 2019;26(7):341-347.

Vivolo-Kantor A, Hoots B, David F, Gladden R. Suspected Heroin Overdose in U.S. Emergency Departments, 2017-2018. American Journal of Public Health, July 2019; 109(7): 1022-1024. doi:10.2105/AJPH.2019.305053

Dowell D, Haegerich T, Chou R. No Shortcuts to Safer Opioid Prescribing. New England Journal of Medicine. 2019;380:2285-2287. doi: 10.1056/NEJMp1904190

Baird J, Faul M, Green T, Howland J, Adams C, Hodne M, Bohlen N, Mello M. Evaluation of a Safer Opioid Prescribing Protocol (SOPP) for Patients Being Discharged From a Trauma Service. Journal of Trauma Nursing, May/June 2019; 26(3):113–120. doi:10.1097/JTN.0000000000000435

Coffey W, Hunter A, Mobley E, Vivolo-Kantor A. Rural-Urban Trends in Opioid Overdose Discharges in Missouri Emergency Departments, 2012-2016. The Journal of Rural Health, 2019 Apr 25: 1-10. doi: 10.1111/jrh.12368.

Nataraj N, Zhang K, Guy G, Losby J. Identifying opioid prescribing patterns for high-volume prescribers via cluster analysis. Drug and Alcohol Dependence, doi: 10.1016/j.drugalcdep.2019.01.012

Schieber L, Guy G, Seth P, Young R, Mattson C, Mikosz C, Schieber R. Trends and Patterns of Geographic Variation in Opioid Prescribing Practices by States, United States, 2006-2017. JAMA Network Open. 2019;2(3):e190665. Doi:10.1001/jamanetworkopen.2019.0665

Guy G, Zhang K, Schieber L, Young R, Dowell D. County-level Opioid Prescribing in the United States, 2015 and 2017. JAMA Internal Med. Published online February 11, 2019; doi:10.1001/jamainternmed.2018.6989

Guy G, Zhang K. Opioid Prescribing by Specialty and Volume in the U.S. AJPM. Published online October 5, 2018. DOI: j.amepre.2018.06.008

Bohnert A, Guy G, Losby J. Opioid Prescribing in the United States Before and After the Centers for Disease Control and Prevention’s 2016 Opioid Guidance. Ann Intern Med. 2018; 169(6):367-375. doi: 10.7326/M18-1243

Lin DH, Jones CM, Compton WM, et. al. Prescription Drug Coverage for Treatment of Low Back Pain Among US Medicaid, Medicare Advantage, and Commercial Insurers. JAMA Network Open. 2018; 1(2), e180235. doi:10.1001/jamanetworkopen.2018.0235

Johnson K, Jones C, Wilson C, et al. Federal Response to the Opioid Crisis. Current HIV/AIDS Report. 2018; 15:293–301. doi: 10.1007/s11904-018-0398-8

Seth P, Rudd R, Noonan, R, Haegerich, T. Quantifying the Epidemic of Prescription Opioid Overdose Deaths. AJPH, 2018; 108(4),e1-e3. doi: 10.2105/AJPH.2017.304265

Houry DE, Haegerich TM, Vivolo-Kantor A. Opportunities for Prevention and Intervention of Opioid Overdose in the Emergency Department. Ann Emerg Med. 2018; 108 (4) 500-502. doi: 10.1016/j.annemergmed.2018.01.052.

Mercado MC, Sumner SA, Spelke MB, Bohm MK, Sugerman DE, Stanley C. Increase in Drug Overdose Deaths Involving Fentanyl—Rhode Island, January 2012–March 2014. Pain Med. 2018; 19(3):511-523. doi: 10.1093/pm/pnx015.

Guy G, Pasalic E, Zhang K. Emergency department visits involving opioid overdoses – United States, 2010-2014. AJPM. 2017; 54 (1) 37-39. doi: j.amepre.2017.09.003

Dowell D, Noonan RK, Houry D. Underlying factors in drug overdose deaths. JAMA. 2017;318(23):2295-2296. doi:10.1001/jama.2017.15971

Dowell D, Arias E, Kochanek K, Anderson R, Guy GP, Losby J, Baldwin G. Contribution of Opioid-Involved Poisoning to the Change in Life Expectancy in the United States, 2000-2015. JAMA. 2017;3 18(11):1065-1067. doi10.1001/jama.2017.9308

Dowell D, Haegerich TM. Changing the Conversation About Opioid Tapering. Ann Intern Med. 2017;167(3):208-209. doi: 10.7326/M17-1402.

Losby JL, Hyatt JD, Kanter MH, Baldwin G, Matsuoka D. Safer and more appropriate opioid prescribing: a large healthcare system’s comprehensive approach. J Eval Clin Pract. 2017;1–7. doi: 10.1111/jep.12756.

Schuchat A, Houry DE, Gery Jr GP. New data on opioid use and prescribing in the United States. JAMA 2017; 318(7):1-2. doi:10.1001/jama.2017.8913

Baird J, Faul M, Green TC, Howland J, Adams CA, George A, Mello MJ. A retrospective review of unintentional opioid overdose risk and mitigating factors among acutely injured trauma patients. Drug and Alcohol Dependence. 2017; 178:130-135. doi: 10.1016/j.drugalcdep.2017.04.030.

Faul M, Lurie P, Kinsman JM, Dailey MW, Crabaugh C, Sasser SM. Multiple Naloxone Administrations Among Emergency Medical Service Providers is Increasing. Prehosp Emerge Care.2017; 21(4): 411-419. doi: 10.1080/10903127.2017.1315203.

Jones CM, Baldwin GT, Compton WM. Recent Increases in Cocaine-Related Overdose Deaths and the Role of Opioids. AJPH. 2017; 107( 3):430-432. doi: 10.2105/AJPH.2016.303627.

Dowell D, Zhang K, Noonan RK, Hockenberry JM. Mandatory provider review and pain clinic laws reduce the amounts of opioids prescribed and overdose death rates. Health Aff .2016; 35(10):1-9. doi: 10.1377/hlthaff.2016.0448

Neven D, Paulozzi L, Howell D, McPherson S, Murphy SM, Grohs B, Marsh L, Lederhos C, Roll J. A Randomized Controlled Trial of a Citywide Emergency Department Care Coordination Program to Reduce Prescription Opioid Related Emergency Department Visits. J Emerg Med51(5) 498-507. doi: 10.1016/j.jemermed.2016.06.057.

Florence CS, Zhou C, Luo F, Xu L. The Economic Burden of Prescription Opioid Overdose, Abuse, and Dependence in the United States, 2013. Med Care.2016; 54(10): 901-906. doi:10.1097/MLR.0000000000000625

Easterling KW, Mack KA, Jones CM. Location of fatal prescription opioid-related deaths in 12 states, 2008-2010: Implications for prevention programs. J Safety Res. 2016; 58:105-109. doi: 10.1016/j. jsr.2016.07.004

Kattan JA, Tuazon E, Paone D, Dowell D, Vo L, Starrels JL, Jones CM, Kunins HV. Public Health Detailing—A Successful Strategy to Promote Judicious Opioid Analgesic Prescribing. AJPH. 2016; 106(8), 1430-1438. doi: 10.2105/AJPH.2016.303274.

Chang HY, Lyapustina T, Rutkow L, Daubresse M, Richey M, Faul M, Stuart EA, Alexander GC. Impact of prescription drug monitoring programs and pill mill laws on high-volume opioid prescribers: A comparative interrupted time series analysis. Drug Alcohol Depend. 2016; 165, 1-8. doi: 10.1016/j.drugalcdep.2016.04.033.

Zhou, C, Florence, C, Dowell, D. Payments For Opioids Shifted Substantially To Public And Private Insurers While Consumer Spending Declined, 1999–2012. Health Aff. 2016; 35(5): 824-831. doi:10.1377/hlthaff.2015.1103.

Sumner SA, Mercado-Crespo MC, Spelke MB, Paulozzi LJ, Sugerman DE, Hillis SD, Stanley C. Use of naloxone by emergency medical services during opioid drug overdose resuscitation efforts. Prehosp Emerg Care. 2016; 20(2):220-225. doi:10.3109/10903127.2015.1076096.

Frieden TR, Houry D. Reducing the risks of relief — the CDC opioid-prescribing guideline. N Engl J Med. 2016. 374: 1501-1504. doi:10.1056/NEJMp1515917.

Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain—United States, 2016; JAMA, Special Communication. Published online March 15, 2016. doi: 1001/jama.2016.1464.

Scott LC, Lewis S. Opioids for Chronic Pain. JAMA Patient Page.; 315(15), 1672. doi:10.1001/jama.2016.3224.

Paulozzi LJ, Zhou C, Jones CM, Xu L, Florence CS. Changes in the medical management of patients on opioid analgesics following a diagnosis of substance abuse. Pharmacoepidemiol Drug Saf.2016; (5)545-52. doi:10.1002/pds.3980.

Compton WM, Jones CM, Baldwin GT, Relationship between Nonmedical Prescription-Opioid Use and Heroin Use. NEJM. 2016; 374:154-163. doi:10.1056/NEJMra1508490.

Lyapustina T, Rutkow L, Chang H, Daubresse M, Ramji AF, Faul M, Stuart EA, and Alexander GC. Effect of a “pill mill” law on opioid prescribing and utilization: The case of Texas. Drug Alcohol Depen. 2016; 159 (1) 109-197. doi:10.1016/j.drugalcdep.2015.12.025.

Fulton-Kehoe D, Sullivan MD, Turner JA, Garg RK, Bauer AM, Wickizer TM, Franklin GM. Opioid Poisonings in Washington State Medicaid. Med Care. 2015; 53 (8), 679 doi:10.1097/MLR.0000000000000384.

Jones C, Campopiano M, Baldwin G, McCance-Katz E. (2015). National and State Treatment Need and Capacity for Opioid Agonist Medication-Assisted Treatment. 2015; 105, (8), 55-63. doi:10.2105/AJPH.2015.302664.

Faul M, Dailey MW, Sugerman DE, Sasser SM, Levy B, Paulozzi LJ. (2015). Disparity in naloxone administration by emergency medical service providers and the burden of drug overdose in US rural communities. AJPH, 2015; 105 (3), 26-32. doi:10.2105/AJPH.2014.302520.

Mack KA, Zhang K, Paulozzi L, Jones C. Prescription Practices involving Opioid Analgesics among Americans with Medicaid, 2010. J Health Care Poor Underserved. 2015;26(1):182-98. doi: 1353/hpu.2015.0009

Haegerich TM, Paulozzi L, Manns B, Jones CJ. What we know and don’t know about state and system level policy strategies to prevent prescription drug overdose. Drug Alcohol Depen.2014; 145: 34-37. doi: 10.1016/j.drugalcdep.2014.10.001.

Jones C, Paulozzi L, Mack K. Sources of prescription opioid pain relievers by frequency of past-year nonmedical use: United States, 2008–2011. JAMA Int Med. 2014; 174(5):802-803. doi:1001/jamainternmed.2013.12809

Baumblatt JA, Wiedeman C, Dunn J, Schaffner W, Paulozzi L, Jones T. High-risk use by patients prescribed opioids for pain and its role in overdose deaths. JAMA Int Med. 2014; 174 (5):796-801. doi:10.1001/jamainternmed.2013.12711

Paulozzi L, Zhang K, Jones C, Mack K. Risk of adverse health outcomes with increasing duration and regularity of opioid therapy. J Am Board Fam Med. 2014; 27 (3): 329-338.doi: 3122/jabfm.2014.03.130290

Sauber-Schatz EK, Mack KA, Diekman ST, Paulozzi LJ, Associations between pain clinic density and distributions of opioid pain relievers, drug-related deaths, hospitalizations, emergency department visits and neonatal abstinence syndrome in Florida. Drug Alc Depend. 2013; 133 (1) 161-166. http://dx.doi.org/10.1016/j.drugalcdep.2013.05.017.

Logan J, Liu Y, Paulozzi LJ, Zhang K, Jones C. Opioid prescribing in emergency departments: the prevalence of potentially inappropriate prescribing and misuse. Med Care. 2013; 51 (8).doi:10.1097.

Jones CM. Heroin use and heroin use risk behaviors among nonmedical users of prescription opioid pain relievers – United States, 2002-2004 and 2008-2010. Drug Alc Depend. 2013; 132 (1-2): 95-100 Available at: http://dx.doi.org/10.1016/j.drugalcdep.2013.01.007.

Jones CM, Mack KA, Paulozzi LJ. Pharmaceutical overdose deaths, United States, 2010. 2013; 309(7):657-659. doi:10.1001/jama.2013.272

Paulozzi LJ. Prescription drug overdoses: a review. J Safety Res. 2012; 43(4): 283-289. org/10.1016/j.jsr.2012.08.009

Jones C. Frequency of prescription pain reliever nonmedical use: 2002-2003 and 2009-2010. Arch Intern Med.2012;172(16):1265- doi:10.1001/archinternmed.2012.2533

Kenan K, Mack K, Paulozzi LJ. Trends in prescriptions for oxycodone and other commonly used opioids in the United States, 2000-2010. Open Med. 2012 Apr 10;6(2):e41-7. doi: PMC3659213

Paulozzi LJ, Kilbourne EM, Shah NG, Nolte KB, Desai HA, Landen MG, Harvey W, Loring LD. A history of being prescribed controlled substances and risk of drug overdose death. Pain Med. 2012; 13 (1):87-95. https://doi.org/10.1111/j.1526-4637.2011.01260.x

Paulozzi LJ, Weisler RH, Patkar AA. A National Epidemic of Unintentional Prescription Opioid Overdose Deaths: How Physicians Can Help Control It. J Clin Psychiatry. 2011; 72(5):589-592.

Paulozzi L, Kilbourne E, Desai H. Prescription drug monitoring programs and death rates from drug overdose. Pain Med. 2011;12:747-754. doi:1111/j.1526-4637.2011.01062.x

Toblin R, Mack K, Perveen G, Paulozzi L. A population-based survey of chronic pain and its treatment with prescription drugs. Pain. 2011; 152(6):1249-55. org/10.1016/j.pain.2010.12.036

Paulozzi LJ, Stier, DD. Prescription drug laws, drug overdoses, and drug sales in New York and Pennsylvania. J Pub Health Policy. 2010; 31422-432. https://doi.org/10.1057/jphp.2010.27

Toblin RL, Paulozzi LJ, Logan JE, Hall AJ, Kaplan JA. Mental illness and psychotropic drug use among prescription drug overdose deaths: a medical examiner chart review J Clin Psych. 2010;71: 491-496.

Paulozzi LJ, Logan JE, Hall AJ, McKinstry E, Kaplan JA. A comparison of drug overdose deaths involving methadone and other opioid analgesics in West Virginia. Addiction. 2009; 104 (9):1541-1548. https://doi.org/10.1111/j.1360-0443.2009.02650.x

Hall AJ, Logan JE, Toblin RL, Kaplan JA, Kraner JC, Bixler D, Crosby AE, Paulozzi LJ. Patterns of abuse among unintentional pharmaceutical overdose fatalities. JAMA 2008; 300(22):2613-2620.

Paulozzi LJ, Xi L. Recent changes in drug poisoning mortality in the United States by urban-rural status and by drug type. Pharmacoepidemiol Drug Saf. 2008;17(10): 997-1005. https://doi.org/10.1002/pds.1626

Paulozzi LJ, Annest J. US data show sharply rising drug-induced death rates. Injury Prevention. 2007;13 (2):130-132. http://dx.doi.org/10.1136/ip.2006.014357

Paulozzi LJ,Ryan GW. Opioid analgesics and rates of fatal drug poisoning in the United States. Am J Prev Med. 2006; 31 (6):506–11. https://doi.org/10.1016/j.amepre.2006.08.017

Paulozzi LJ. Opioid analgesic involvement in drug abuse deaths in the American metropolitan areas. AJPH. 2006; 96 (10):1755-1757. doi:10.2105/AJPH.2005.071647

Paulozzi LJ, Budnitz DS, Xi Y. Increasing deaths from opioid analgesics in the United States. Pharmacoepidemiol and Drug Saf. 2006; 15 (9):618-627. org/10.1002/pds.1276